{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:24:11Z","timestamp":1794000251951,"version":"4.8.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtocrr.2026.101010","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:58:08Z","timestamp":1777733888000},"page":"101010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"7","author":[{"given":"Elsa","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Maistrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101010_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101010_bib2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101010_bib3","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2026.101010_bib4","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jtocrr.2026.101010_bib5","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1177\/09622802221085864","article-title":"Generalized quasi-linear mixed-effects model","volume":"31","author":"Saigusa","year":"2022","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jtocrr.2026.101010_bib6","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtocrr.2026.101010_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/bimj.201900036","article-title":"Meta-analysis of the difference of medians","volume":"62","author":"McGrath","year":"2020","journal-title":"Biom J"},{"key":"10.1016\/j.jtocrr.2026.101010_bib8","series-title":"Systematic Reviews in Health Care: Meta-analysis in Context","first-page":"285","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","author":"Deeks","year":"2001"},{"key":"10.1016\/j.jtocrr.2026.101010_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","author":"Higgins","year":"2008","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series"},{"key":"10.1016\/j.jtocrr.2026.101010_bib10","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.jtocrr.2026.101010_bib11","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/bmj.322.7300.1479","article-title":"Forest plots: trying to see the wood and the trees","volume":"322","author":"Lewis","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.jtocrr.2026.101010_bib12","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jtocrr.2026.101010_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104538","article-title":"Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy","volume":"10","author":"Chiang","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtocrr.2026.101010_bib14","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.24.00553","article-title":"Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update","volume":"42","author":"Dowlati","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101010_bib15","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jtocrr.2026.101010_bib16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s11864-024-01268-3","article-title":"Tarlatamab-dlle: a new hope for patients with extensive-stage small-cell lung cancer","volume":"25","author":"Goyal","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jtocrr.2026.101010_bib17","series-title":"Tarlatamab for Extensive-Stage Small-Cell Lung Cancer After 2 or More Treatments","year":"2025"},{"key":"10.1016\/j.jtocrr.2026.101010_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12094-025-03980-4","article-title":"Bispecific T-cell engagers (BiTE): a review of tarlatamab in small cell lung cancer","volume":"28","author":"Ogieuhi","year":"2026","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jtocrr.2026.101010_bib19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","article-title":"Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin Lung Cancer"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:27:37Z","timestamp":1793996857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666364326000615"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101010","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101010"}}